MIAMI, August 7, 2026
NRx Pharmaceuticals announced that the U.S. Food and Drug Administration (FDA) has completed the first-cycle review of the company’s Abbreviated New Drug Application (ANDA) for preservative-free intravenous ketamine (NRX-100) without identifying any major deficiencies related to the drug product, active ingredients, proposed labeling, Chemistry, Manufacturing and Controls (CMC), or other drug-related review matters. According to the company, no additional clinical, safety, efficacy, or drug-related data are required for approval. The only remaining issue involves manufacturer certification for the product’s luer lock vial packaging system, which the FDA classified as a major deficiency because it relates to the container closure system rather than the medicine itself. Following a clarification meeting with senior FDA leadership on August 6, 2026, the agency outlined a clear path toward resolution and committed to reviewing the requested certification in the shortest possible review cycle, significantly strengthening the product’s regulatory outlook..
Packaging Certification Represents Final Regulatory Requirement
The remaining FDA request focuses on documentation confirming that the luer lock medication vial is manufactured using the same production lines and methods as similar FDA-approved generic products already on the market. According to NRx, the packaging configuration is currently used in three FDA-approved ANDA products that collectively shipped approximately 11.9 million units during the past 12 months without complaints, recalls, adverse events, or product returns. The company also submitted operational testing data covering more than 3,500 vials manufactured across seven production lots, with no failures observed in luer lock performance. Following discussions with FDA officials, NRx is submitting manufacturer attestations confirming identical manufacturing processes and the established commercial safety record of the packaging system. The agency indicated that once this certification is reviewed, the regulatory process can move forward without requesting additional drug-related studies.
Regulatory Progress Supports Commercialization Strategy
Completion of the first review cycle without significant drug-related deficiencies is viewed by NRx as an important milestone, particularly given industry data suggesting that only 14% to 18% of ANDA applications receive approval during the first review cycle. The company believes this outcome substantially reduces regulatory risk and improves its readiness for commercialization. NRx also noted that prompt approval could help address the ongoing FDA-listed ketamine shortage while strengthening domestic production of a strategically important medicine. Unlike currently marketed intravenous ketamine formulations, NRX-100 is preservative-free, addressing concerns associated with preservatives no longer permitted in newly approved drugs, topical antiseptics, and hand sanitizers. Company leadership also highlighted the product’s potential role in supporting national initiatives focused on expanding access to innovative mental health treatments, particularly for veterans and patients suffering from severe psychiatric disorders.
Advertisement
NRX-100 Development Continues Alongside Broader CNS Pipeline
NRX-100 is being developed as a preservative-free intravenous ketamine formulation targeting suicidal ideation associated with depression, including bipolar depression, and has already received FDA Fast Track Designation. In parallel, NRx is advancing NRX-101, an investigational oral therapy that has received Breakthrough Therapy Designation for suicidal bipolar depression. The company plans to provide investors with additional regulatory updates, commercialization plans, and pipeline progress during a conference call scheduled for August 10, 2026. With the FDA confirming that no new clinical or manufacturing data related to the ketamine formulation itself are required, NRx now focuses on completing the final packaging certification process, bringing the preservative-free ketamine ANDA closer to potential approval and commercial launch.
Source:NRx Pharmaceuticals press release
